FI110003B - Menetelmä anti-CDw52-vasta-aineen puhdistamiseksi ja vasta-ainetta sisältävän formulaation valmistamiseksi - Google Patents

Menetelmä anti-CDw52-vasta-aineen puhdistamiseksi ja vasta-ainetta sisältävän formulaation valmistamiseksi Download PDF

Info

Publication number: FI110003B
Authority: FI; Finland
Prior art keywords: antibody; column; protein; cdw52; campath
Prior art date: 1990-10-17

Application number

FI922380A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI922380A0 (fi

FI922380A (fi

Inventor

Paul Ian Nicholas Ramage

Geoffrey Allen

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-17

Filing date

1992-05-25

Publication date

2002-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI110003(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-05-25 Application filed by Wellcome Found filed Critical Wellcome Found

1992-05-25 Publication of FI922380A0 publication Critical patent/FI922380A0/fi

1992-05-25 Publication of FI922380A publication Critical patent/FI922380A/fi

1992-06-17 Priority to FI922824A priority Critical patent/FI110002B/fi

2002-11-15 Application granted granted Critical

2002-11-15 Publication of FI110003B publication Critical patent/FI110003B/fi

Links

238000000034 method Methods 0.000 title claims description 34
239000000203 mixture Substances 0.000 title claims description 16
238000009472 formulation Methods 0.000 title description 6
108090000623 proteins and genes Proteins 0.000 claims abstract description 50
102000004169 proteins and genes Human genes 0.000 claims abstract description 39
229920002684 Sepharose Polymers 0.000 claims abstract description 16
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 12
239000002245 particle Substances 0.000 claims abstract description 11
230000007717 exclusion Effects 0.000 claims abstract description 9
238000005342 ion exchange Methods 0.000 claims abstract description 7
239000002253 acid Substances 0.000 claims abstract description 6
230000002378 acidificating effect Effects 0.000 claims abstract description 4
150000002500 ions Chemical class 0.000 claims abstract description 3
230000008569 process Effects 0.000 claims description 10
239000007864 aqueous solution Substances 0.000 claims description 5
238000005341 cation exchange Methods 0.000 claims description 4
238000011068 loading method Methods 0.000 claims description 4
239000003929 acidic solution Substances 0.000 claims description 2
238000005349 anion exchange Methods 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000012679 serum free medium Substances 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 13
238000001542 size-exclusion chromatography Methods 0.000 abstract description 6
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 abstract description 5
239000000356 contaminant Substances 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 62
229940112129 campath Drugs 0.000 description 38
235000018102 proteins Nutrition 0.000 description 31
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
238000002360 preparation method Methods 0.000 description 19
239000000499 gel Substances 0.000 description 17
101150074155 DHFR gene Proteins 0.000 description 16
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
229960000485 methotrexate Drugs 0.000 description 16
239000012071 phase Substances 0.000 description 14
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
239000002609 medium Substances 0.000 description 11
230000005526 G1 to G0 transition Effects 0.000 description 10
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000012505 Superdex™ Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
108010047041 Complementarity Determining Regions Proteins 0.000 description 8
230000003321 amplification Effects 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000000463 material Substances 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
238000000926 separation method Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000010828 elution Methods 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
238000004366 reverse phase liquid chromatography Methods 0.000 description 6
229910001868 water Inorganic materials 0.000 description 6
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
229930193140 Neomycin Natural products 0.000 description 5
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
235000019253 formic acid Nutrition 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
239000000178 monomer Substances 0.000 description 5
229960004927 neomycin Drugs 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
239000001888 Peptone Substances 0.000 description 4
108010080698 Peptones Proteins 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
102000005396 glutamine synthetase Human genes 0.000 description 4
108020002326 glutamine synthetase Proteins 0.000 description 4
230000028993 immune response Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
235000019319 peptone Nutrition 0.000 description 4
239000011148 porous material Substances 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
239000013598 vector Substances 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 3
101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
102100024952 Protein CBFA2T1 Human genes 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000007639 printing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
238000011012 sanitization Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
241000894007 species Species 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000011282 treatment Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000003656 tris buffered saline Substances 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
239000004201 L-cysteine Substances 0.000 description 2
235000013878 L-cysteine Nutrition 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
229930195722 L-methionine Natural products 0.000 description 2
229930182821 L-proline Natural products 0.000 description 2
239000012480 LAL reagent Substances 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108090000295 Nucellin Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
108010040201 Polymyxins Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
238000010276 construction Methods 0.000 description 2
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
238000012258 culturing Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940014144 folate Drugs 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
150000002605 large molecules Chemical class 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
229960002429 proline Drugs 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229960002898 threonine Drugs 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
239000013621 viresolve pro solution Substances 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
235000019158 vitamin B6 Nutrition 0.000 description 2
239000011726 vitamin B6 Substances 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
UUVPYTIBUIBXTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-7-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2C(N)=NC(N)=NC2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 UUVPYTIBUIBXTJ-ZDUSSCGKSA-N 0.000 description 1
JHUNGZQPXRVEDL-XIFFEERXSA-N (2s)-n,n'-didecyl-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanediamide Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)NCCCCCCCCCC)C(=O)NCCCCCCCCCC)=CC=C1N(C)CC1=CN=C(N=C(N)N=C2N)C2=N1 JHUNGZQPXRVEDL-XIFFEERXSA-N 0.000 description 1
239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
FCWXSQNGFGSDMO-UHFFFAOYSA-N 2-iodoacetamide;2-iodoacetic acid Chemical compound NC(=O)CI.OC(=O)CI FCWXSQNGFGSDMO-UHFFFAOYSA-N 0.000 description 1
LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
PMJHNEFCWLUZBC-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1=C(N)C(C)(C)CC(C=2C=C(C)C(N)=CC=2)=C1 PMJHNEFCWLUZBC-UHFFFAOYSA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010065524 CD52 Antigen Proteins 0.000 description 1
102000013135 CD52 Antigen Human genes 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
101150074355 GS gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
239000002211 L-ascorbic acid Substances 0.000 description 1
235000000069 L-ascorbic acid Nutrition 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102100031953 Protein 4.2 Human genes 0.000 description 1
101710196267 Protein 4.2 Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
150000002009 diols Chemical group 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000012454 limulus amebocyte lysate test Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000010187 selection method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
239000011686 zinc sulphate Substances 0.000 description 1
235000009529 zinc sulphate Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FI922380A 1990-10-17 1992-05-25 Menetelmä anti-CDw52-vasta-aineen puhdistamiseksi ja vasta-ainetta sisältävän formulaation valmistamiseksi FI110003B (fi)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
FI922824A FI110002B (fi)	1990-10-17	1992-06-17	Menetelmä puhdistetun IgG-vasta-ainevalmisteen saamiseksi

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB909022547A GB9022547D0 (en)	1990-10-17	1990-10-17	Purified immunoglobulin
GB9022547		1990-10-17
PCT/GB1991/001816 WO1992007084A1 (en)	1990-10-17	1991-10-17	Purified cdw52-specific antibodies
GB9101816		1991-10-17

Publications (3)

Publication Number	Publication Date
FI922380A0 FI922380A0 (fi)	1992-05-25
FI922380A FI922380A (fi)	1992-05-25
FI110003B true FI110003B (fi)	2002-11-15

Family

ID=10683866

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI922380A FI110003B (fi)	1990-10-17	1992-05-25	Menetelmä anti-CDw52-vasta-aineen puhdistamiseksi ja vasta-ainetta sisältävän formulaation valmistamiseksi
FI922824A FI110002B (fi)	1990-10-17	1992-06-17	Menetelmä puhdistetun IgG-vasta-ainevalmisteen saamiseksi

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FI922824A FI110002B (fi)	1990-10-17	1992-06-17	Menetelmä puhdistetun IgG-vasta-ainevalmisteen saamiseksi

Country Status (29)

Country	Link
US (1)	US5644036A (pt)
EP (1)	EP0504363B2 (pt)
JP (1)	JP2638680B2 (pt)
KR (2)	KR960015399B1 (pt)
AT (2)	ATE162552T1 (pt)
AU (3)	AU658926B2 (pt)
BE (1)	BE1004226A5 (pt)
BR (1)	BR1100358A (pt)
CA (1)	CA2069481C (pt)
CH (2)	CH681305A5 (pt)
DE (1)	DE69128774T3 (pt)
DK (1)	DK0504363T4 (pt)
ES (2)	ES2081742B1 (pt)
FI (2)	FI110003B (pt)
FR (2)	FR2668164A1 (pt)
GB (2)	GB9022547D0 (pt)
GR (3)	GR910100425A (pt)
HU (1)	HUT64601A (pt)
IE (1)	IE913560A1 (pt)
IL (3)	IL99761A0 (pt)
IT (1)	IT1250064B (pt)
LU (1)	LU88122A1 (pt)
MX (1)	MX9203794A (pt)
MY (2)	MY119030A (pt)
NZ (2)	NZ240247A (pt)
PT (2)	PT99248B (pt)
TW (1)	TW283710B (pt)
WO (1)	WO1992007084A1 (pt)
ZA (2)	ZA926191B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
AU671807B2 (en) *	1991-10-15	1996-09-12	Btg International Limited	CDw52 - specific antibody for treatment of T-cell mediated inflammation of the joints
GB9125768D0 (en) *	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
GB9300501D0 (en) *	1993-01-09	1993-03-03	Wellcome Found	Purification of immunoglobulin
CA2228128C (fr) †	1995-08-01	2011-03-29	Pasteur Merieux Serums & Vaccins	Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
CZ292465B6 (cs)	1996-02-09	2003-09-17	Abbott Laboratories (Bermuda) Ltd.	Lidské protilátky k lidskému TNFalfa
GB9603256D0 (en) *	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US20030023043A1 (en) *	2000-03-02	2003-01-30	Kazuhisa Uchida	Method of separating and purifying protein
EP2336149A1 (en)	2001-03-09	2011-06-22	Chugai Seiyaku Kabushiki Kaisha	Protein purification method
DE60213248T2 (de) *	2001-06-05	2006-11-30	Genetics Institute, LLC, Cambridge	Verfahren zur reinigung hochanionischer proteine
GB0220894D0 (en) *	2002-09-09	2002-10-16	Millipore Uk Ltd	Method of separation
EP2261230B1 (en)	2002-09-11	2017-05-10	Chugai Seiyaku Kabushiki Kaisha	Protein purification method
CN1705679B (zh)	2002-10-15	2011-04-06	英特塞尔股份公司	编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
GB0304576D0 (en) *	2003-02-28	2003-04-02	Lonza Biologics Plc	Protein a chromatography
CA2548947A1 (en) *	2003-12-22	2005-07-14	Genzyme Corporation	Anti-cd52 antibody treatment for diabetes
PT1869065T (pt)	2005-03-11	2020-06-18	Wyeth Llc	Método de cromatografia de partição fraca
US9096651B2 (en)	2007-09-26	2015-08-04	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
PL3514180T3 (pl)	2008-04-11	2024-08-12	Chugai Seiyaku Kabushiki Kaisha	Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
MY160126A (en)	2009-05-13	2017-02-28	Genzyme Corp	Anti-human cd52 immunoglobulins
WO2010132683A1 (en)	2009-05-13	2010-11-18	Genzyme Corporation	Methods and compositions for treating lupus
WO2011090719A2 (en) *	2009-12-29	2011-07-28	Dr. Reddy's Laboratories Ltd.	Protein purification by ion exchange
EP2583973B1 (en)	2010-06-21	2018-03-21	Kyowa Hakko Kirin Co., Ltd.	Method for purifying protein using amino acid
RU2467783C2 (ru) *	2010-07-30	2012-11-27	Закрытое акционерное общество "БиоХимМак СТ"	Способ хроматографического выделения иммуноглобулина
TWI812066B (zh)	2010-11-30	2023-08-11	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) *	2011-06-01	2011-07-13	Antitope Ltd	Antibodies
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en)	2012-08-07	2017-05-16	Kyowa Hakko Kirin Co., Ltd.	Method of purifying protein
SG11201504249XA (en)	2012-09-02	2015-07-30	Abbvie Inc	Methods to control protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
EP2830651A4 (en)	2013-03-12	2015-09-02	Abbvie Inc	HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) *	2013-03-15	2016-10-06	Takeda Pharmaceutical Company Limited	Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es)	2013-03-15	2015-09-30	Genzyme Corp	Anticuerpos anti-cd52
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CA2935143C (en)	2013-12-27	2024-05-07	Chugai Seiyaku Kabushiki Kaisha	Method for purifying antibody having low isoelectric point
AR103161A1 (es)	2014-12-19	2017-04-19	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
WO2017022651A1 (ja)	2015-07-31	2017-02-09	中外製薬株式会社	アニオン性ポリマーによる抗体を含有する組成物の精製方法
CA3031028C (en)	2016-07-25	2024-02-13	Lu Wang	Affinity chromatography wash buffer
TW202300168A (zh)	2016-08-05	2023-01-01	日商中外製藥股份有限公司	Il-8相關疾病之治療用或預防用組成物
US20220177518A1 (en)	2019-03-29	2022-06-09	Asahi Kasei Medical Co., Ltd.	Method for purifying protein
US20220212167A1 (en)	2019-04-08	2022-07-07	Asahi Kasei Medical Co., Ltd.	Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
KR20210149779A (ko)	2019-04-10	2021-12-09	추가이 세이야쿠 가부시키가이샤	Fc 영역 개변 항체의 정제 방법
KR20240021151A (ko)	2021-06-10	2024-02-16	미쯔비시 케미컬 주식회사	합성 흡착제, 항체의 정제 방법 및 항체의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118796A (en) *	1987-12-09	1992-06-02	Centocor, Incorporated	Efficient large-scale purification of immunoglobulins and derivatives
CA1339198C (en) *	1988-02-12	1997-08-05	Gregory Paul Winter	Antibodies to the antigen campath-1

1990
- 1990-10-17 GB GB909022547A patent/GB9022547D0/en active Pending
1991
- 1991-10-16 IL IL99761A patent/IL99761A0/xx unknown
- 1991-10-16 BE BE9100946A patent/BE1004226A5/fr not_active IP Right Cessation
- 1991-10-16 MY MYPI91001909A patent/MY119030A/en unknown
- 1991-10-16 IE IE356091A patent/IE913560A1/en not_active IP Right Cessation
- 1991-10-16 IT ITRM910788A patent/IT1250064B/it active IP Right Grant
- 1991-10-16 IL IL10272691A patent/IL102726A/en not_active IP Right Cessation
- 1991-10-16 GR GR910100425A patent/GR910100425A/el unknown
- 1991-10-16 FR FR9112738A patent/FR2668164A1/fr active Granted
- 1991-10-16 MY MYPI92001385A patent/MY136210A/en unknown
- 1991-10-16 NZ NZ240247A patent/NZ240247A/en not_active IP Right Cessation
- 1991-10-16 ZA ZA926191A patent/ZA926191B/xx unknown
- 1991-10-16 ZA ZA918259A patent/ZA918259B/xx unknown
- 1991-10-16 NZ NZ244114A patent/NZ244114A/en not_active IP Right Cessation
- 1991-10-16 TW TW080108178A patent/TW283710B/zh not_active IP Right Cessation
- 1991-10-16 PT PT99248A patent/PT99248B/pt not_active IP Right Cessation
- 1991-10-17 ES ES09250029A patent/ES2081742B1/es not_active Expired - Lifetime
- 1991-10-17 AT AT91917891T patent/ATE162552T1/de not_active IP Right Cessation
- 1991-10-17 AT AT0900791A patent/ATA900791A/de not_active Application Discontinuation
- 1991-10-17 ES ES91917891T patent/ES2112865T5/es not_active Expired - Lifetime
- 1991-10-17 CA CA002069481A patent/CA2069481C/en not_active Expired - Lifetime
- 1991-10-17 DK DK91917891T patent/DK0504363T4/da active
- 1991-10-17 WO PCT/GB1991/001816 patent/WO1992007084A1/en active IP Right Grant
- 1991-10-17 CH CH1901/92A patent/CH681305A5/fr not_active IP Right Cessation
- 1991-10-17 DE DE69128774T patent/DE69128774T3/de not_active Expired - Lifetime
- 1991-10-17 KR KR1019920701427A patent/KR960015399B1/ko not_active IP Right Cessation
- 1991-10-17 EP EP91917891A patent/EP0504363B2/en not_active Expired - Lifetime
- 1991-10-17 CH CH2655/92A patent/CH681455A5/fr not_active IP Right Cessation
- 1991-10-17 JP JP3516509A patent/JP2638680B2/ja not_active Expired - Lifetime
- 1991-10-17 HU HU9202000A patent/HUT64601A/hu unknown
1992
- 1992-02-28 GB GB9209529A patent/GB2253397A/en not_active Withdrawn
- 1992-05-25 FI FI922380A patent/FI110003B/fi not_active IP Right Cessation
- 1992-05-27 LU LU88122A patent/LU88122A1/xx unknown
- 1992-06-17 FI FI922824A patent/FI110002B/fi not_active IP Right Cessation
- 1992-06-29 MX MX9203794A patent/MX9203794A/es unknown
- 1992-08-04 IL IL102726A patent/IL102726A0/xx unknown
- 1992-08-13 FR FR9209998A patent/FR2677997A1/fr not_active Withdrawn
- 1992-09-23 AU AU25321/92A patent/AU658926B2/en not_active Expired
- 1992-10-20 GR GR920100471A patent/GR920100471A/el unknown
- 1992-10-20 PT PT100988A patent/PT100988B/pt not_active IP Right Cessation
- 1992-10-30 KR KR1019920702699A patent/KR100193314B1/ko not_active IP Right Cessation
1994
- 1994-08-11 AU AU70242/94A patent/AU7024294A/en not_active Abandoned
- 1994-10-07 US US08/319,598 patent/US5644036A/en not_active Expired - Lifetime
1997
- 1997-04-28 BR BR1100358-8A patent/BR1100358A/pt active IP Right Grant
- 1997-11-13 AU AU45218/97A patent/AU716402B2/en not_active Expired
1998
- 1998-04-10 GR GR980400777T patent/GR3026588T3/el unknown

Also Published As

Publication number	Publication date
FI922380A0 (fi)	1992-05-25
AU658926B2 (en)	1995-05-04
CH681305A5 (pt)	1993-02-26
TW283710B (pt)	1996-08-21
IL102726A (en)	2002-08-14
ES2112865T5 (es)	2007-09-16
CA2069481A1 (en)	1992-04-18
ZA926191B (en)	1993-04-16
GB2253397A (en)	1992-09-09
KR100193314B1 (ko)	1999-06-15
KR960015399B1 (ko)	1996-11-13
CA2069481C (en)	2003-07-29
MX9203794A (es)	1992-07-01
DE69128774T2 (de)	1998-06-04
GR920100471A (el)	1994-06-30
ES2081742A1 (es)	1996-03-01
PT100988B (pt)	1999-08-31
NZ244114A (en)	1995-06-27
GB9209529D0 (en)	1992-07-01
HU9202000D0 (en)	1992-10-28
ATA900791A (de)	1996-06-15
JP2638680B2 (ja)	1997-08-06
FI922824A (fi)	1992-06-17
JPH05504579A (ja)	1993-07-15
IL102726A0 (en)	1993-01-31
AU2532192A (en)	1993-02-11
AU649078B2 (en)	1994-05-12
PT100988A (pt)	1994-02-28
DE69128774T3 (de)	2007-08-16
FR2668164A1 (fr)	1992-04-24
CH681455A5 (pt)	1993-03-31
IT1250064B (it)	1995-03-30
FR2668164B1 (pt)	1995-04-14
MY119030A (en)	2005-03-31
EP0504363A1 (en)	1992-09-23
WO1992007084A1 (en)	1992-04-30
BE1004226A5 (fr)	1992-10-13
HUT64601A (en)	1994-01-28
US5644036A (en)	1997-07-01
EP0504363B2 (en)	2007-02-07
AU7024294A (en)	1995-01-05
ITRM910788A0 (it)	1991-10-16
ES2081742B1 (es)	1996-10-01
FI110002B (fi)	2002-11-15
MY136210A (en)	2008-08-29
PT99248A (pt)	1993-06-30
ATE162552T1 (de)	1998-02-15
IE913560A1 (en)	1992-04-22
BR1100358A (pt)	2000-03-28
FR2677997A1 (fr)	1992-12-24
DE69128774D1 (de)	1998-02-26
EP0504363B1 (en)	1998-01-21
FI922380A (fi)	1992-05-25
FI922824A0 (fi)	1992-06-17
DK0504363T4 (da)	2007-05-29
ES2112865T3 (es)	1998-04-16
ZA918259B (en)	1993-04-16
ITRM910788A1 (it)	1993-04-16
GR910100425A (el)	1992-09-25
KR920703108A (ko)	1992-12-17
GB9022547D0 (en)	1990-11-28
IL99761A0 (en)	1992-08-18
DK0504363T3 (da)	1998-09-21
NZ240247A (en)	1994-03-25
PT99248B (pt)	1999-04-30
LU88122A1 (fr)	1993-03-15
GR3026588T3 (en)	1998-07-31
AU8729491A (en)	1992-05-20
AU716402B2 (en)	2000-02-24
AU4521897A (en)	1998-02-12

Publication	Publication Date	Title
FI110003B (fi)	2002-11-15	Menetelmä anti-CDw52-vasta-aineen puhdistamiseksi ja vasta-ainetta sisältävän formulaation valmistamiseksi
IE84931B1 (en)		Purified IgG Antibodies
CA2053585C (en)	2006-08-29	Antibody production in chinese hamster ovary cells
JP6417016B2 (ja)	2018-10-31	抗ｐ２ｘ７受容体抗体およびその断片
US20090136509A1 (en)	2009-05-28	Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions
CA1338324C (en)	1996-05-14	Monoclonal antibody for the selective immunological determination of intact procollagen peptide (type iii) and procollagen (type iii) in body fluids
EP0792162B1 (en)	2005-11-09	Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
US5430129A (en)	1995-07-04	Purified, native dystrophin
AU649078C (en)	1995-04-13	Purified CDW52-specific antibodies
WO2024027771A1 (zh)	2024-02-08	靶向FAP和TGFβ的抗体融合蛋白及其用途
EP0368466B1 (en)	1995-11-29	Compositions and methods for the treatment and prevention of gram-negative bacterial infections
WO1994015950A1 (en)	1994-07-21	Purification of immunoglobulin
WO2025006898A1 (en)	2025-01-02	Anti-idiotypic antibodies to cluster of differentiation 7-targeted binding domains and related compositions and methods
Leibl et al.	1990	Multiple infusions of human intravenous immunoglobulin in chimpanzees do not lead to immune elimination
JPH08325296A (ja)	1996-12-10	抗体、ハイブリドーマおよびそれらの用途

Legal Events

Date	Code	Title	Description
2011-11-25	MA	Patent expired